last_updated: 1405941241
is_oa: False
cited_by_posts_count: 11
images: {u'small': u'https://altmetric-badges.a.ssl.fastly.net/?size=64&score=4&types=ettttttf', u'large': u'https://altmetric-badges.a.ssl.fastly.net/?size=180&score=4&types=ettttttf', u'medium': u'https://altmetric-badges.a.ssl.fastly.net/?size=100&score=4&types=ettttttf'}
altmetric_id: 643603
subjects: [u'hematology']
published_on: 1325376000
title: The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.
cited_by_tweeters_count: 7
scopus_subjects: [u'Immunology and Microbiology', u'Medicine', u'Health Sciences', u'Biochemistry, Genetics and Molecular Biology', u'Life Sciences']
tq: [u'Our new paper on rationally designed combination of targeted therapy for Hodgkin lymphoma', u'The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgki... PM']
score: 3.85
altmetric_jid: 4f6fa60e3cf058f610006cba
pmid: 22408261
abstract: The pan-deacetylase inhibitor panobinostat (LBH589) recently has been shown to have significant clinical activity in patients with relapsed Hodgkin lymphoma, but its mechanism of action in Hodgkin lymphoma remains unknown. In this study, we demonstrate that panobinostat has potent antiproliferative activity against Hodgkin lymphoma-derived cell lines. At the molecular level, panobinostat activated the caspase pathway, inhibited STAT5 and STAT6 phosphorylation, and down-regulated hypoxia-inducible factor 1 Î± and its downstream targets, glucose transporter 1 (GLUT1) and vascular endothelial growth factor. Paradoxically, panobinostat inhibited LKB1 and AMP-activated protein kinase, leading to activation of mammalian target of rapamycin (mTOR) that promotes survival. Combining panobinostat with the mTOR inhibitor everolimus (RAD001) inhibited panobinostat-induced mTOR activation and enhanced panobinostat antiproliferative effects. Collectively, our data demonstrate that panobinostat is a potent deacetylase inhibitor against Hodgkin lymphoma-derived cell lines, and provide a mechanistic rationale for combining panobinostat with mTOR inhibitors for treating Hodgkin lymphoma patients. Furthermore, the effect of panobinostat on GLUT1 expression suggests that panobinostat may modulate the results of clinical diagnostic imaging tests that depend of functional GLUT1, such as fluorodeoxyglucose positron emission tomography.
schema: 1.5.4
cohorts: {u'doc': 1, u'sci': 1, u'pub': 5}
readers_count: 13
journal: Blood
publisher_subjects: [{u'scheme': u'era', u'name': u'Cardiovascular Medicine And Haematology'}, {u'scheme': u'era', u'name': u'Clinical Sciences'}, {u'scheme': u'era', u'name': u'Paediatrics And Reproductive Medicine'}]
details_url: http://www.altmetric.com/details.php?citation_id=643603
cited_by_peer_review_sites_count: 1
doi: 10.1182/blood-2011-01-331421
abstract_source: pubmed
url: http://dx.doi.org/10.1182/blood-2011-01-331421
readers: {u'mendeley': 13, u'citeulike': 0, u'connotea': 0}
nlmid: 7603509
history: {u'6d': 1, u'1w': 1, u'1y': 1, u'1m': 1, u'6m': 1, u'2d': 1, u'at': 3.85, u'3m': 1, u'5d': 1, u'4d': 1, u'1d': 1, u'3d': 1}
context: {u'similar_age_journal_3m': {u'count': 98, u'higher_than': 91, u'pct': 92, u'rank': 7, u'mean': 1.2851134020619}, u'all': {u'count': 2290306, u'higher_than': 1794255, u'pct': 78, u'rank': 491691, u'mean': 4.8083730865561}, u'similar_age_3m': {u'count': 70253, u'higher_than': 59428, u'pct': 84, u'rank': 10707, u'mean': 3.9010547742412}, u'journal': {u'count': 4602, u'higher_than': 3963, u'pct': 86, u'rank': 627, u'mean': 2.4605107585308}}
cited_by_fbwalls_count: 1
issns: [u'1528-0020']
added_on: 1331435906
cited_by_accounts_count: 9
